Latest filing published 15 Nov 2018 for Apellis Pharmaceuticals, Inc., €26k.
Insider track record
Steven Axon: trading record in brief
This profile gathers the share dealings of Steven Axon in Apellis Pharmaceuticals, Inc. In total, 2 filings cover trades dated from 20 February 2018 to 14 November 2018.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
On 15 November 2018 came the latest disclosure, an option exercise for €26k in Apellis Pharmaceuticals, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Steven Axon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 11,500 shares@ US$2.5924.6% of flowCommon StockSEC:0001127602-18-033263:0
- 38,610 shares@ US$2.5975.4% of flowCommon StockSEC:0000899243-18-004829:0
2 of 2 declarations
